Continuing Medical Education Program in The Journal of Clinical Hypertension


  • Michael A. Weber MD

If you wish to receive credit for this activity, please refer to the website:

Accreditation and Designation Statement

Blackwell Futura Media Services designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Educational Objectives

At the conclusion of this activity, participants will be able to:

  •  Discuss the current clinical research in hypertension that adds to the body of scientific evidence in the treatment of patients with hypertension.
  •  Apply their awareness and knowledge of current clinical research and scientific evidence that will contribute to the overall care of patients with hypertension and other cardiovascular disease factors.
  •  Discuss the efficacy, safety, and tolerability of the different pharmacologic treatment modalities that modulate the renin-angiotensin-aldosterone system to reduce blood pressure and mitigate the negative consequences of poor blood pressure control.
  •  Identify high-risk patient characteristics and determine optimal therapy to achieve target blood pressure.

Activity Disclosures

This activity is supported through an educational grant from Daiichi Sankyo, Inc., and Takeda Pharmaceuticals North America, Inc.

Faculty Disclosures  Addison A. Taylor, M.D., Ph.D. - discloses research grants received as an independent contractor from Novartis Pharmaceuticals.

Helmy Siragy, M.D. – discloses no relevant financial relationships.

Shawna Nesbitt, M.D. – discloses honorarium received for consultant services from Daiichi Sankyo, and honorarium received for consultant/speaker services from Novartis Pharmaceuticals.

This manuscript underwent peer review in line with the standards of editorial integrity and publication ethics maintained by TheJournal of Clinical Hypertension. The peer reviewers disclose the following relevant financial relationships: Honorarium received for speaker/consultant services from Takeda Pharmaceuticals, Daiichi Sankyo, Novartis Pharmaceuticals, and Forest Pharmaceuticals; grant received for research from Daiichi Sankyo. The peer review process for TheJournal of Clinical Hypertension is single-blinded. As such, the identities of the reviewers are not disclosed in line with the standard accepted practices of medical journal peer review.

Conflicts of interest have been identified and resolved in accordance with Blackwell Futura Media Services’s Policy on Activity Disclosure and Conflict of Interest. The primary resolution method used was peer review and review by a non-conflicted expert.

Instructions on Receiving Credit

For information on applicability and acceptance of CME credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within an hour; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to two years from initial publication.

Follow these steps to earn credit:

  •  Log on to
  •  Read the target audience, educational objectives, and activity disclosures.
  •  Read the article in print or online format.
  •  Reflect on the article.
  •  Access the CME Exam, and choose the best answer to each question.
  •  Complete the required evaluation component of the activity.

This activity will be available for CME credit for twelve months following its publication date. At that time, it will be reviewed and potentially updated and extended for an additional twelve months.

Disclosure:  The authors received no honoraria for their contribution to this issue.